Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Filed Chapter 11
Director departure
Appointed director
Quarterly results
K-V Pharmaceutical Co (KV.A) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2011 8-K Asset disposition
Docs: "K-V PHARMACEUTICAL COMPANY ANNOUNCES THE COMPLETION OF THE SALE OF NESHER PHARMACEUTICALS, INC. ITS GENERIC PHARMACEUTICAL BUSINESS Divestiture of the Company's Generic Assets Consistent with K-V's Strategic Focus on the Specialty Branded Pharmaceutical Sector St. Louis, MO - August 8, 2011, - K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc. , the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals , Inc and Zynesher Pharmaceuticals LLC . The aggregate sales price for the transaction is $60 million of which $7.5 million will be held in an escrow arrangement for post-closing indemnification purposes. The purchase includes the physical..."
07/08/2011 8-K Asset disposition
Docs: "Consent of BDO USA, LLP",
"Consent of KPMG LLP",
"Consolidated Financial Statements and Notes thereto for the fiscal year ended March 31, 2011, updated to disclose condensed consolidating financial information"
09/10/2010 8-K Asset disposition
Docs: "Letter dated August 5, 2010, from LNR Partners, LLC to MECW, LLC and K-V Pharmaceutical Company",
"K-V PHARMACEUTICAL COMPANY ANNOUNCES COMPLETION OF U.S. FOOD AND DRUG ADMINISTRATION INSPECTION AND APPROVAL TO RETURN ITS FIRST PRODUCT TO MARKET September 10, 2010, St. Louis, MO. - K-V Pharmaceutical Company announced today that it has received notice from the U.S. Food and Drug Administration of the successful completion of an inspection of the Company's facilities and approval to return its first product to market. Under the Company's Consent Decree, successful FDA inspections of the Company's quality systems, processes and facilities are expected to be required before K-V is permitted to resume manufacturing and shipment of particular products. During the week of August 16, 2010, the FDA undertook an inspection of the Company's quality systems, manufacturing processes and facilities ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy